Aunins John G. 4
4 · Seres Therapeutics, Inc. · Filed Jan 31, 2020
Insider Transaction Report
Form 4
Aunins John G.
CTO and EVP of Bioprocess Dev.
Transactions
- Award
STOCK OPTION (RIGHT TO BUY)
2020-01-29+300,000→ 300,000 totalExercise: $3.30Exp: 2030-01-28→ Common Stock (300,000 underlying)
Footnotes (1)
- [F1]The option will vest as to 25% of the shares on January 29, 2021. The remainder of the shares will vest in 12 equal quarterly installments thereafter.